AMGN
39
-2
ABT
62
9
NUE
50
2
SRE
49
-5
USB
46
-2
TROW
48
8
RCL
77
-6
F
35
-4
ACN
38
2
LNC
45
-8
PPL
52
-7
SE
52
2
MDT
62
3
KMI
65
-4
CMA
52
-3
KMB
33
2
BMY
43
-3
PVH
57
2
DG
23
2
CAT
57
2
AMGN
39
-2
ABT
62
9
NUE
50
2
SRE
49
-5
USB
46
-2
TROW
48
8
RCL
77
-6
F
35
-4
ACN
38
2
LNC
45
-8
PPL
52
-7
SE
52
2
MDT
62
3
KMI
65
-4
CMA
52
-3
KMB
33
2
BMY
43
-3
PVH
57
2
DG
23
2
CAT
57
2
Financhill
Back

Supernus Pharmaceuticals Quote, Financials, Valuation and Earnings

U.S. Government Report Alert Tuesday

Discover the Secret Loophole
Sell
41

SUPN
Supernus Pharmaceuticals

Last Price:
34.66
Seasonality Move:
8.24%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Supernus Pharmaceuticals Price Quote

$34.66
+0.69 (+2.03%)
(Updated: November 4, 2024 at 5:55 PM ET)

Supernus Pharmaceuticals Key Stats

Sell
41
Supernus Pharmaceuticals (SUPN) is a Sell
Day range:
$33.70 - $34.96
52-week range:
$23.05 - $35.56
Dividend yield:
0%
P/E ratio:
1,738.00
P/S ratio:
3.05
P/B ratio:
2%
Volume:
788.8K
Avg. volume:
299.5K
1-year change:
42.07%
Market cap:
$1.9B
Revenue:
$607.5M
EPS:
$0.09

How Much Does Supernus Pharmaceuticals Make?

Is Supernus Pharmaceuticals Growing As A Company?

Supernus Pharmaceuticals Stock Price Performance

What Is Supernus Pharmaceuticals 52-Week High & Low?

Supernus Pharmaceuticals Price To Free Cash Flow

Is It Risky To Buy Supernus Pharmaceuticals?

Is Supernus Pharmaceuticals Cash Flow Positive?

  • What Is SUPN Cash Flow From Operations?
    Cash flow from operations (TTM) is $154.9M
  • What Is Supernus Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $4.1M
  • What Is Supernus Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$131.6M

Supernus Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    SUPN return on invested capital is 0.57%
  • What Is Supernus Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is 0.41%
  • What Is SUPN Return On Equity?
    ROE is a measure of profitability and is 0.57%

Supernus Pharmaceuticals Earnings Date & Stock Price

Supernus Pharmaceuticals Competitors

Supernus Pharmaceuticals Dividend Yield

Supernus Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 71.44%
Revenue: 24.17% 13.08%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 39.25
Upside from Last Price: 15.54%

Major Shareholders

  • How many SUPN shares are owned by institutional investors?
    91.1M SUPN shares are owned by institutional investors
  • How many SUPN shares are owned by insiders?
    1.6M SUPN shares are owned by insiders